JenaValve Archives - Medical Design Sourcing

The biggest cardiovascular stories from TCT 2023

Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT.

This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco.

Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE HealthCare and more had positive updates on their own technologies.

Last year’s TCT event highlighted some significant trends in the cardiovascular space. Let’s see what this year’s symposium brought.

Abbott’s TriClip, MitraClip shine along with drug-eluting stent

Results from Abbott’s TRILUMINATE pivotal trial reinforced the safety and effectiveness of the TriClip system. Abbott also shared data from the MitraClip EXPAND G4 real-world registry at TCT 2023.

TriClip, a transcatheter edge-to-edge repair (TEER) system, treats patients with symptomat…

TAVR tech developer JenaValve adds former J&J vet to its board

New JenaValve board member Shlomi Nachman. [Image from J&J]JenaValve Technology announced that it appointed cardiovascular industry veteran Shlomi Nachman to its board of directors.

Nachman brings more than 25 years of experience to the transcatheter aortic valve replacement (TAVR) system maker’s board. He previously held senior operating roles at Johnson & Johnson. That included serving as company group chair of cardiovascular and specialty solutions and vision groups within J&J Medical Devices.

He was a member of the company’s medical devices group operating committee as well. At J&J, Nachman led a portfolio of six different medical device businesses. Before that, he had various roles, including worldwide president of Biosense Webster and Cordis.

“We are thrilled to welcome Shlomi to the JenaValve board of directors,” said John Kilcoyne, JenaValve CEO. “His experience as both an executive and board member across innovative card…

JenaValve completes enrollment in TAVR trial

JenaValve announced today that it successfully completed patient enrollment in a trial evaluating its Trilogy heart valve system.

Irvine, California-based JenaValve develops and manufactures differentiated transcatheter aortic valve replacement (TAVR) systems. It designed Trilogy for high surgical risk patients with symptomatic, severe aortic regurgitation (AR).

JenaValve’s prospective, single-arm ALIGN-AR trial is operating under FDA investigational device exemption. The company designed the trial to assess the Trilogy heart valve system in high-risk patients with symptomatic, severe aortic regurgitation (ssAR).

Last week, the company closed a $100 million Series C financing round. It said it planned to use proceeds to complete its IDE trial for Trilogy. It plans to use results to support a future premarket approval (PMA) submission to the FDA.

“Completing the ALIGN-AR trial is a significant step forward for the cardiology community in addr…

JenaValve raises $100M Series C for TAVR tech

JenaValve Technology announced today that it completed the initial closing of a $100 million Series C financing round.

Irvine, California-based JenaValve develops and manufactures differentiated transcatheter aortic valve replacement (TAVR) systems.

The company intends to use proceeds from the financing to complete its FDA investigational device exemption (IDE) premarket approval (PMA) study to garner FDA approval for the Trilogy heart valve system. JenaValve designed Trilogy for high surgical risk patients with symptomatic, severe aortic regurgitation (AR).

Additionally, the company plans to use the proceeds to bolster its real-world data development initiatives in Europe. JenaValve also plans to expand its worldwide manufacturing capabilities.

“JenaValve is committed to becoming the first and only FDA-approved transfemoral transcatheter valve system indicated for symptomatic, severe aortic regurgitation, addressing an estimated multi-billion-dol…